ArticleAMB Express2025
Study of anti-Toxoplasma gondii effect of mPEG-PCL copolymeric loaded with pyrimethamine, in vitro.
Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pyrimethamine Triggers the Apoptotic Pathway in Mucoepidermoid Carcinoma in Cell-Based Models.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of new drugs with minimal toxicity is crucially important in the search for effective treatments for toxoplasmosis. The study aimed to assess the effectiveness of pyrimethamine-loaded mPEG-PCL copolymeric nanoparticles (mPEG-PCL-Pyr) against Toxoplasma gondii (T. gondii) tachyzoites. The nanoparticles were fabricated using a nano-precipitation method and characterized using DLS and AFM. Through MTT assay, the anti-toxoplasmic activity was gauged. Healthy and infected cell viability, infection index, proliferation index, plaque count, and size were evaluated. Results indicated a maximum drug loading capacity of 11.23% in the nanoparticles. Toxicity testing on Vero cells infected with tachyzoites revealed notable cytotoxic effects at pyrimethamine-equivalent concentrations of 20 and 40 mg/mL in the mPEG-PCL copolymeric nanoparticle formulation. However, as the results indicated, the administration of mPEG-PCL-Pyr resulted in the reduction of intracellular proliferation, infection index, and the number and size of plaques in comparison to uninfected treated cells (P < 0.05). The synthesized Nano drug exhibited slightly better performance than pyrimethamine, despite the lack of statistical significance in the observed distinction (p > 0.05). The study demonstrated that mPEG-PCL copolymeric nanoparticles containing pyrimethamine effectively impede the in vitro replication of T. gondii. The study demonstrated that mPEG-PCL copolymeric nanoparticles containing pyrimethamine effectively impede the in vitro replication of T. gondii. The impact of pyrimethamine resembled that of the synthesized nano-drug on T. gondii tachyzoites, suggesting the potential of these nanoparticles as a promising avenue for toxoplasmosis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.